Department of Respiratory Diseases, Santa Maria Nuova Hospital, Reggio, Emilia, Italy.
Allergy Asthma Clin Immunol. 2011 May 24;7(1):9. doi: 10.1186/1710-1492-7-9.
Currently, omalizumab is indicated for the treatment of patients with severe allergic uncontrolled asthma despite optimal therapy.
We studied a 52-year-old man who has been suffering from severe non allergic steroid-resistant asthma with increased levels of total IgE and a lot of comorbidity. After a 3 years long treatment with omalizumab, he presented a significant improvement in disease control in terms of hospitalizations, exacerbation, quality of life and lung function with good safety profile.
Our case shows, after a long follow-up, how omalizumab can be effective in a severe form of non-atopic asthma. It is therefore hoped that further studies can identify indicators that are able to give to clinicians information about patients who can be responsive to monoclonal anti-IgE antibody even if non allergic.
目前，奥马珠单抗适用于治疗尽管接受了最佳治疗但仍存在严重过敏且无法控制的哮喘患者。
我们研究了一名 52 岁男性患者，他患有严重的非变应性类固醇耐药性哮喘，总 IgE 水平升高且存在许多合并症。经过 3 年奥马珠单抗治疗，他在住院、恶化、生活质量和肺功能方面的疾病控制得到了显著改善，安全性良好。
我们的病例表明，经过长期随访，奥马珠单抗如何在非变应性严重哮喘中有效。因此，希望进一步的研究能够确定指标，以便为临床医生提供有关可对单克隆抗 IgE 抗体有反应的患者的信息，即使是非变应性患者。
